Panagora Asset Management’s Lipocine LPCN Stock Holding History

Panagora Asset Management’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,307	Closed	-$43K	–	2554
2019 Q2	$43K	Sell	1,307 -27	-2%	-$833	﹤0.01%	2114
2019 Q1	$52K	Buy	+1,334	New	+$40.9K	﹤0.01%	2028
2015 Q4	–	Sell	-307	Closed	-$62K	–	2334
2015 Q3	$62K	Buy	+307	New	+$71K	﹤0.01%	1939

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

Choreo LLC Rockford, Illinois $8.15B AUM 20.12% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Panagora Asset Management's LPCN Position: Q3 2019 in Review

Panagora Asset Management sold out of Lipocine (LPCN) in Q3 2019, closing a stake of 1,307 shares — an estimated $43K sold.

Panagora Asset Management first reported a position in LPCN in Q3 2015 and held it in 3 quarters. The position peaked at $62K in Q3 2015. 30 funds tracked by Wall St. Rank hold LPCN as of Q3 2019.

Panagora Asset Management reported no remaining Lipocine position as of Q3 2019 after selling out during the quarter.
Panagora Asset Management sold 1,307 Lipocine shares in Q3 2019, an estimated $43K.
Panagora Asset Management first reported a position in Lipocine in Q3 2015 and held it in 3 quarters.
Panagora Asset Management's Lipocine position peaked at $62K in Q3 2015.
30 funds tracked by Wall St. Rank held Lipocine as of Q3 2019.

Based on Panagora Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.